Cytek Biosciences (CTKB) Cost of Revenue (2020 - 2026)

Cytek Biosciences' Cost of Revenue history runs 7 years deep, the most recent figure standing at $22.9 million for Q1 2026.

• Quarterly Cost of Revenue rose 7.42% year-over-year to $22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.6 million (up 11.05% YoY) and the FY2025 annual result came in at $97.0 million, up 8.6% from the prior year.
• Cost of Revenue was $22.9 million for Q1 2026 at Cytek Biosciences, down from $29.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $29.3 million in Q4 2025 and bottomed at $13.6 million in Q3 2022.
• A 5-year average of $20.9 million and a median of $21.5 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue soared 52.93% — and 2024, when it slipped 5.4%.
• Cytek Biosciences' Cost of Revenue stood at $19.0 million in 2022, then soared by 32.82% to $25.2 million in 2023, then decreased by 5.4% to $23.8 million in 2024, then gained by 22.8% to $29.3 million in 2025, then retreated by 21.79% to $22.9 million in 2026.
• Business Quant data shows CTKB's Cost of Revenue at $22.9 million in Q1 2026, $29.3 million in Q4 2025, and $24.7 million in Q3 2025.